146 results about "Plasma sample" patented technology

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

The application discloses a method for determining unbound concentration of lenvatinib, which comprises the following steps: sending standard curve working solution and quality control working solution into a liquid chromatography tandem mass spectrometry detection system to obtain a standard curve; adding a plasma sample into an ultrafiltration tube, centrifuging under the condition of a centrifugal force of 3000g for 15 min, and collecting an ultrafiltrate of the plasma sample; adding the ultrafiltrate of the plasma sample into blank plasma ultrafiltrate, mixing uniformly, taking supernatant into a collection plate, sending the collection plate into the liquid chromatography tandem mass spectrometry detection system to obtain a ratio of a peak area of lenvatinib to a peak area of an internal standard, and then bringing the area ratio into the standard curve to obtain the unbound concentration of lenvatinib in the plasma sample. The method for determining the unbound concentration of lenvatinib can accurately determine the unbound concentration of lenvatinib in plasma and overcome the prejudice of the prior art.

Systems, methods and computer-readable media are provided for identifying patients having an elevated near-term risk of chronic kidney disease (CKD) progression, including predicting an individual's risk of progression to Stage 3 CKD within a future time interval, which may be up to 36 months. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In an embodiment, measurements of physiological variables are obtained, including serial measurements for uric acid levels from a longitudinal time series of serum or plasma samples spanning the previous two to five years. An annualized uric acid velocity of the patient is determined and used to generate a multivariable mathematical model for determining a likelihood of risk for developing Stage 3 CKD within 36 months.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.

Disclosed is a method for diagnosing a cancer health status, or a change in cancer health status, or for diagnosing a risk of cancer change or presence in a patient, comprising determining in a plasma sample from the patient one or more biomarker values corresponding to a complex structure containing alpha-1 antitrypsin (A1AT), and based on the biomarker values, determining the patient as suffering or not suffering from cancer, or having or not having a change in cancer health status, or having or not having a risk of cancer, wherein the cancer is selected from the group consisting of hepatocellular carcinoma (HCC), ovarian cancer (OC), and breast cancer (BC).

The invention provides a method for simultaneously determining ritocaine and prilocaine in blood plasma based on a liquid chromatography-tandem mass spectrometry (LC-MSMS) technology. The specific operation of the method comprises the following steps: adding an internal standard solution and an organic solvent into a plasma sample, and ensuring full extraction of lidocaine and prilocaine through vortex mixing. And separating by using a centrifugal technology, and collecting supernate as a pretreated sample to be detected. An Eclipse Plus C18 chromatographic column is adopted for isocratic elution, effective separation of lidocaine and prilocaine is achieved, and then a sample is subjected to mass spectrometric detection. A standard curve is drawn based on the mass spectrum peak area ratio, a regression equation is obtained, and the concentration of lidocaine and prilocaine in the sample to be detected is obtained through calculation. The method has the characteristics of simplicity and convenience in pretreatment operation, low plasma consumption, short analysis time and high sensitivity, and is suitable for detection of lidocaine and prilocaine in plasma and clinical pharmacokinetic research of the lidocaine cream.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to transthyretin-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).

The invention provides a pretreatment method for mass spectrometric detection of plasma protein and a kit. A plurality of plasma treatment means are combined by comprehensively applying acetonitrile; the serum specifically comprises 10% of whole plasma, 20% of acetonitrile precipitate, 10% of 40% acetonitrile precipitate, 20% of 50% acetonitrile supernatant, and 20% of supernatant obtained by removing albumin after precipitating the plasma with 10% and 20% of polyethylene glycol respectively. Deep proteomic analysis is carried out on the redistributed plasma sample, 5441 proteins are identified from 5336 genes, and proteins with the concentration as low as nanogram / upgrade are detected. On the premise that common abundance proteins are not removed, more than 5000 proteins are successfully identified under the conditions of about 100 non-tandem components and 2-hour gradient operation, and the maximum scale of mass spectrum-based plasma proteomics research is achieved.

The invention discloses an i-motif DNA (deoxyribonucleic acid) modified gold nano flare, a preparation method of the i-motif DNA modified gold nano flare and application of the i-motif DNA modified gold nano flare to detection of miRNA, and belongs to the technical field of nano biological materials and molecular diagnosis. The fluorescence probe is formed by assembling gold nanoparticles and an i-motif molecular fluorescence probe, the i-motif molecular fluorescent probe contains four sections of sequences rich in C basic groups and a target miRNA recognition chain, sulfydryl is marked at the 5'end, and fluorescent molecules are marked at the 3 'end. The probe is prepared by adopting a freeze thawing method, the labeling density of the probe is high, in a constructed detection system, the miR-21 detection limit is as low as 1.01 fM, and single-base mutants can be accurately distinguished; the technology does not need complex sample pretreatment and can be directly used for detecting cell total RNA or miRNA in a plasma sample, and the detection result is highly consistent with RT-qPCR; the problems of low marking efficiency and insufficient sensitivity in the prior art are effectively solved, and an innovative tool with high sensitivity, high specificity and clinical suitability is provided for tumor-associated miRNA molecular diagnosis.

The application provides a plasma exosome purification system, and belongs to the field of biomedical engineering. The system comprises: an affinity chromatography pretreatment module, which is used for specifically adsorbing exosomes from a plasma sample, and obtaining an exosome eluate through washing and elution; an ultrasonic nanofiltration module, which is used for filtering the exosome eluate under the action of ultrasonic waves to retain the exosomes and remove small molecular impurities, and obtaining an exosome concentrate; a pipetting module, which is used for performing liquid transfer operations of the plasma sample, the washing liquid, the eluate and the exosome eluate among the modules; and a main control module, which is in communication connection with the pipetting module and is used for controlling the pipetting module to perform the liquid transfer operations. The application combines the affinity chromatography and ultrasonic nanofiltration purification technologies, and realizes automatic pipetting control with the help of the main control module and the pipetting module, thereby significantly improving the purity of separation and purification while ensuring the integrity of the exosomes.

1. The name of the design product: fluorescent immunoassay analyzer (RealG-FL12 Pro). 2. The use of the design product: a medical testing device for detecting the analyte in human whole blood, serum and plasma samples, etc., using fluorescent immunoassay technology to excite and measure the fluorescent signal, thereby realizing rapid identification and quantitative analysis of pathogens, and providing important information for the diagnosis and treatment of infectious diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The utility model relates to the technical field of biological medicine, and discloses a plasma sample derivatization treatment device which comprises a treatment tank, an extension sleeve disc is fixedly connected to the outer surface of the treatment tank, a supporting block is jacked through a hydraulic rod, a connecting shaft and a fishing disc are driven to move upwards from the bottom of the treatment tank, and the treatment tank is driven to rotate. When the fishing disc reaches the position where the adsorption pipe is located, due to the fact that the notch groove in the surface of the fishing disc is matched with the adsorption pipe and the notch groove and the adsorption pipe are combined, the air pump is started, and the air pump adsorbs the non-polar biological matrix in the fishing disc through the adsorption pipe; then the adsorbed non-polar biological matrix is conveyed into the impurity box, so that the problems of incomplete cleaning, low efficiency and the like possibly existing in a traditional manual cleaning mode are avoided, and meanwhile, the adverse effect on subsequent detection work caused by matrix residues is also effectively avoided; and the conditions of inaccurate detection result, damage to detection equipment and the like which are possibly caused by matrix residue are solved.

This invention provides a set of metabolic biomarkers for assessing perfluorooctane sulfonate (PFOS) exposure levels and their applications, belonging to the field of organic pollutant poisoning detection technology. Utilizing plasma sample metabolomics data and machine learning algorithms, this invention successfully constructs a discriminant model capable of accurately distinguishing between high PFOS exposure (above 20 ng / mL) and low exposure (not exceeding 20 ng / mL). This method is simple to operate, non-invasive, and the sample collection process is quick and easy, making it particularly suitable for large-scale PFOS high exposure risk screening in populations. It eliminates the need for PFOS standards, avoiding potential contamination risks.

The invention discloses a method for detecting the concentration of Hetrombopag in human plasma through high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: adding an internal standard Eltrombopag-13C4 and a precipitator into a plasma sample, uniformly mixing, centrifuging, and taking a supernatant; performing high performance liquid chromatography-tandem mass spectrometry detection on the supernate, and calculating by combining a standard curvilinear equation to obtain the concentration of the Hytrombopag in the human plasma. Through methodology verification of specificity, accuracy, precision, matrix effect, dilution reliability, residue, stability and the like, the detection method can be applied to detection analysis and pharmacokinetic research of a clinical patient hitrombopag plasma sample, so that the use dosage of the medicine is reasonably adjusted, and a safer and more effective individualized medication scheme is provided for the patient.

The present application relates to the technical field of biological medicine, in particular to a lipid metabolite combination for early diagnosis of VKH and application thereof, by obtaining plasma samples of patients with initial acute stage (early stage) VKH syndrome and healthy controls, and constructing sample-full lipid quantitative expression matrix, screening differential lipids through PCA unsupervised analysis and OPLS-DA supervised model, further screening lipids with high diagnostic performance by using elastic net logistic regression model, finally obtaining a diagnostic marker combination composed of 25 lipid metabolites, solving the technical problems of existing VKH diagnosis technology, such as invasiveness, insufficient sensitivity and stability of protein marker detection, limited diagnostic efficiency, lack of systematicness and standardized process in lipidomics research, achieving the effect of non-invasive, efficient, high sensitivity and high specificity of early auxiliary diagnosis of VKH syndrome, and providing objective and reliable technical means for precise identification of atypical cases and large-scale clinical screening.

The present invention relates to a method based on miRNA biomarkers and clinical data for risk stratification of non-metastatic breast cancer of any molecular subtype according to the risk of developing remote metastasis, preferably in a fresh frozen sample or formalin-immobilized paraffin embedded (FFPE) sample, or in a liquid biopsy sample (serum or plasma sample). More particularly, the present invention relates to the use of 2-miRNA profiles in a prognostic model comprising two miRNAs and biomarkers that have been applied to clinical management of breast cancer patients.

The present invention is entitled "A Method for Determining Solanesol Content in Plasma and Its Application", belonging to the field of pharmaceutical research and development technology. The technical problem to be solved is that solanesol cannot be effectively detected in plasma sample matrix. The key points of the technical solution are the determination method, which includes the following steps: (1) Plasma pretreatment: mix plasma with internal standard solution and acetonitrile, centrifuge to obtain supernatant; (2) Detection: use liquid chromatography-tandem mass spectrometry to perform chromatographic separation and mass spectrometry detection on the supernatant; (3) Calculation: calculate the solanesol content in plasma according to the internal standard method.

The invention discloses a method for extracting protein from human plasma for protein analysis, and relates to the technical field of plasma treatment, the key points of the technical scheme are as follows: the method effectively removes high-abundance protein, lipid and other interfering substances in the plasma through two steps of protein precipitation with acetone, degreasing and high-abundance protein removal; the method is suitable for subsequent protein identification and quantitative analysis. A stable and reliable method is provided for pretreatment of the plasma sample, a technical basis is provided for further use of protein in plasma for various medical analyses, and further development of the technology in the plasma detection field is facilitated.

This invention relates to a method for preparing a plasma sample containing amyloid β-peptides for mass spectrometry analysis, comprising the following steps: a) contacting the plasma sample with a denaturing agent; b) performing a first solid-phase extraction step on the solution obtained in step a) to recover a first eluent; c) performing a second solid-phase extraction step on the first eluent obtained in step b) to recover a second eluent; and d) drying the second eluent obtained in step c) and processing it for mass spectrometry analysis, wherein the solution obtained in step d) contains intact amyloid β-peptides Aβ40 and Aβ42.

The invention discloses a structure annotation method for analyzing positions sn-and C = C of lipid based on liquid chromatography-organic matter ion electron collision excitation mass spectrometry. According to the method, a proper amount of 0.1 mM sodium acetate is added during lipid redissolution, so that polar lipid and neutral lipid are analyzed at the same time through one-time sample introduction. Meanwhile, a method for automatically annotating the complex organic matter ion electron collision excitation mass spectrum is developed, and the method comprises the steps of (1) extracting mass spectrum information in original data, (2) identifying lipid subclasses, (3) matching lipid total composition, (4) pairing sn-position, (5) positioning C = C position, and (6) determining annotation level. For 34 lipid standard substances in serum, the annotation accuracy rates of the annotation method on sn-and C = C isomer levels are 100% and 82.3% respectively. A total of 1312 sn-isomers and 1033 C = C isomers are annotated from mixed plasma samples of healthy people and patients with mild cognitive impairment of Alzheimer's disease. In a word, the lipid fine structure analysis method developed by the invention has the characteristics of simple pretreatment, high coverage and efficient annotation of the lipid fine structure.

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The application discloses a kind of for HBV PreS1 antibody qualitative detection test strip and its preparation method and application, it is related to virology, immunology, biological detection technology and immunochromatography analysis technical field.The test strip is based on the specific recognition principle of antigen and antibody, the specific binding of PreS1 antigen and PreS1 antibody is realized, the rapid detection of PreS1 antibody in serum or plasma sample, it is sequentially assembled by sample pad, gold mark pad, nitrocellulose membrane (NC membrane) and water absorption pad, wherein, gold mark pad is fixed with colloidal gold labeled anti-human IgG antibody as gold mark probe, NC membrane detection line (T line) is coated HBV PreS1 antigen, for capturing PreS1 antibody in sample, NC membrane quality control line (C line) is coated HB2 antibody, for judging whether the test strip detection process is effective.The test strip in the application does not need complex instrument equipment, detection process is simple, fast and fast, and has good sensitivity and specificity, can be used for hepatitis B vaccine immune effect evaluation and large-scale screening.

A disposable bioassay diagnostic cartridge for performing enzyme-linked immunosorbent assay for a single patient in whole blood and plasma where the cartridge has a plurality of wells. The cartridge includes a pipette tip with internal sidewalls disposed in one well of the plurality of wells, the internal sidewalls being pretreated and coated with antibodies, a reagent mixture disposed in another well of the plurality of wells, the reagent mixture comprising at least one reagent selected from the group consisting of pH stabilizer, ionic catalyst control agent, ionic intracellular inhibitory control agent, detergent, negative control agent, chelating agent, and biocide preservative, antibody, and conjugate stabilizing agent. At least a chromogenic substrate and visualizing reagent disposed in an integrated cuvette of the plurality of wells. It also includes the detection of the hemoglobin amount in the blood sample so a correction for plasma amount in a sample can be performed.

The invention discloses a method for efficiently detecting trace residues of'three-high 'drugs in fish plasma, the'three-high' drugs comprise triamterene, terazosin, rosiglitazone, lovastatin, benazepril, pitavastatin and repaglinide, and the method comprises the following steps: adding an anticoagulant into a collected fish plasma sample, centrifuging, taking supernate, and collecting the supernate; the method comprises the following steps: firstly, adding an internal standard solution, adding acetone containing formic acid with the volume fraction of 1% into a purification tube, loading a labeled sample, pressurizing to ensure that the sample drips in a drop shape, collecting by using a polypropylene test tube containing a purification reagent, oscillating and purifying, centrifuging, taking supernate, and concentrating to obtain a concentrated solution; the method disclosed by the invention is high in sensitivity, and the detection limit range of seven kinds of drugs for target'three highs' in the blood plasma of the aquatic environment fish is 0.02-0.25 ng / mL.

The invention provides application of a group of plasma metabolism markers in preparation of a reagent product for pulmonary nodule diagnosis, and relates to the technical field of disease diagnosis reagents. The metabolic marker is prepared from trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin, and the metabolic marker is prepared from the following raw materials: the trigonelline, the 4-methylcatechol, the 2, 4-dinitrophenol, the 3, 4-dihydroxyphenylacetic acid, the N-( According to the application, ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC / MS) is adopted to carry out metabonomics analysis on plasma samples before and after an early pulmonary nodule operation, and a group of plasma metabolites (trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin) are identified; and the group of metabolites is utilized to form a diagnosis model, so that benign and malignant pulmonary nodules can be accurately diagnosed, and early-stage differential diagnosis and risk assessment are facilitated.

The application provides a liquid chromatography-mass spectrometry method for detecting phytosterol content in dried blood spots, and belongs to the technical field of detection.The application simplifies a sampling process, uses a disposable blood taking needle and a blood taking card for sampling, replaces traditional serum or plasma samples with obtained dried blood spots, punches a sampling area of the dried blood spot sample through a puncher with a diameter of 3.2 mm, takes three dried blood spot samples, extracts seven kinds of sterol substances contained in the dried blood spot samples through n-hexane, adopts liquid chromatography-mass spectrometry, carries out detection and quantification through chromatographic separation and a mass spectrometry detector, realizes rapid and accurate determination of cholesterols, beta-sitosterols, daidzein, campesterol, dihydrocholesterol, dehydrocholesterol and 7-alkenyl cholestanol, and the method is simple in operation, accurate in quantification, and has a recovery rate of 92.4%-96.7%.

The application relates to a method for quantitatively detecting the concentration of thioctic acid in human plasma by liquid chromatography-tandem mass spectrometry, and belongs to the technical field of biological sample detection. The method comprises the following steps: EDTA-K2 anticoagulant human plasma is taken, thioctic acid-d5 internal standard working solution is added, the mixture is uniformly mixed, acetonitrile is added to precipitate proteins, the supernatant is taken by centrifugation and is diluted; a C18 chromatographic column is used, 0.1% acetic acid aqueous solution and acetonitrile are used as mobile phases for gradient elution; mass spectrometric detection adopts an electrospray ion source negative ion mode and a multiple reaction monitoring mode, the ion pair of thioctic acid is m / z 205.100->171.100, and the ion pair of the internal standard is m / z 210.050->174.100; the peak area ratio is used as a quantitative index, 1 / C 2 weighted linear regression is used to establish a standard curve. The method has the advantages of simple pretreatment, high sensitivity, rapid analysis, strong anti-matrix interference ability, and is suitable for the detection of conventional and hemolytic and hyperlipidemic plasma samples, and can be used for pharmacokinetic research and clinical detection of thioctic acid.